share_log

Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25

Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25

Truist Securities維持對Marinus Pharma的買入,將目標股價下調至25美元
Benzinga ·  2023/11/08 10:11

Truist Securities analyst Joon Lee maintains Marinus Pharma (NASDAQ:MRNS) with a Buy and lowers the price target from $32 to $25.

Truist Securities分析師李俊維持Marinus Pharma(納斯達克股票代碼:MRNS)的買入,並將目標股價從32美元下調至25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論